Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30313129 | 1.00 | ALDH1A1 (0.54) | ALDH1A1HPGDCYP3A4TDP1HTR3E | |
| SCHEMBL6357932 | 0.86 | ALDH1A1 (0.69) | ALDH1A1HPGDCYP3A4TDP1HTR3E | |
| SCHEMBL945783 | 0.82 | HTR3E (0.50) | ALDH1A1HPGDCYP3A4TDP1HTR3E | |
| SCHEMBL5891689 | 0.81 | CYP3A4 (0.73) | ALDH1A1HPGDCYP3A4TDP1MAPT | |
| SCHEMBL29648847 | 0.80 | CYP3A4 (0.56) | ALDH1A1HPGDCYP3A4TDP1MAPT | |
| SCHEMBL29510769 | 0.80 | CYP3A4 (0.59) | ALDH1A1HPGDCYP3A4TDP1HTR3E | |
| SCHEMBL1019299 | 0.80 | CYP3A4 (0.56) | ALDH1A1HPGDCYP3A4TDP1MAPT | |
| SCHEMBL124245 | 0.80 | CYP3A4 (0.59) | ALDH1A1HPGDCYP3A4TDP1HTR3E | |
| SCHEMBL29538723 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP3A4TDP1MAPT | |
| SCHEMBL374346 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDCYP3A4TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115386245-A | Preparation method and application of lipophilic carbon nitride nanosheet | 浙江理工大学 | 2022-11-25 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-4423094-B1 | RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL MYERS SQUIBB CO (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240417369-A1 | RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-19 | — | — | US | disclosed |
| EP-4423094-A1 | RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Bristol-Myers Squibb Company (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-118176197-A | RXFP1 modulators for the treatment of heart failure | 百时美施贵宝公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-RE49698-E1 | Substituted dihydroquinazolines | AIC246 AG & CO. KG (DE) | 2023-10-17 | — | — | US | disclosed |
| WO-2023077041-A1 | RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| WO-1997026300-A1 | COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES | ELI LILLY AND COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0693053-A1 | UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 1996-01-24 | — | — | EP | disclosed |
| WO-1994022807-A1 | UREA AND AMIDE DERIVATIVES AND THEIR USE IN THE CONTROL OF CELL MEMBRANE POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 1994-10-13 | — | — | WO | disclosed |
| US-4725608-A | ANTIINFLAMMATORY, ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| EP-0144853-A2 | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
| US-4088766-A | PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4001256-A | PROSTAGLANDIN PRODUCTION IN MAMMALS | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | ALDH1A1 4150/4885HPGD 3614/4885CYP3A4 3128/4885 |
| US-20240417369-A1 | RXFP1 AGONISTS | RXFP1, RXFP2, RXFP3 | ALDH1A1 1820/4885HPGD 882/4885CYP3A4 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.